Company intelligence / Profile preview
Dewpoint Therapeutics
Boston/Cambridge area, Massachusetts, United Statesdewpointx.com ↗
- Ownership
- Private
- Employees
- ~150
- Development stage
- Preclinical
01
Overview
Dewpoint has advanced its proprietary platform to the point of nominating clinical candidates. Two programs are expected to enter IND-enabling studies in 2025—one each for colorectal cancer and ALS. The company’s approach has attracted major pharma partnerships and significant investment but no published human clinical results yet
- Therapeutic areas
- CardiovascularEndocrinologyOncologyRare DiseasesNeurologyInfectious Diseases
- Modalities
- Small molecules (condensate modulators or "c-mods")
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Dewpoint Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dewpoint Therapeutics.